Shanghai Haohai Biological Technology Co Ltd 2017 AR2
The report highlights Shanghai Haohai Biological Technology Co., Ltd.'s financial and operational performance for the fiscal year 2017. The company recorded aggregate revenue of approximately RMB 1,344.86 million, representing a 58.0% increase compared to 2016, driven by acquisitions in the ophthalmology sector and steady growth in medical aesthetics. Key achievements include the acquisition of a 70% stake in Contamac Holdings, securing upstream material supply for its intraocular lens (IOL) business. Additionally, its rhEGF 'Healin' product was reclassified to Class B medical insurance, boosting sales by 41.3%. The company also increased its R&D investments by 61.5% to RMB 76.33 million, with its IOL project selected for the National Key R&D Programs.
Company: Shanghai Haohai Biological Technology Co Ltd
Sector: Manufacturing
Country: China
Year: 2017
Type: AR2
Pages: 155
Back to company
Shanghai Haohai Biological Technology Co Ltd
Annual Report
The report highlights Shanghai Haohai Biological Technology Co., Ltd.'s financial and operational performance for the fiscal year 2017. The company recorded aggregate revenue of approximately RMB 1,344.86 million, representing a 58.0% increase compared to 2016, driven by acquisitions in the ophthalmology sector and steady growth in medical aesthetics. Key achievements include the acquisition of a 70% stake in Contamac Holdings, securing upstream material supply for its intraocular lens (IOL) business. Additionally, its rhEGF 'Healin' product was reclassified to Class B medical insurance, boosting sales by 41.3%. The company also increased its R&D investments by 61.5% to RMB 76.33 million, with its IOL project selected for the National Key R&D Programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees